An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Bone Marrow Transplantation

• Publication date

  1997-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bmt.1700891PMID 9339748
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology

  2004cited by this paper
• Pharmacokinetics of high-dose busulfan in children

  2004cited by this paper
• Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation

  2004cited by this paper
• Gas-chromatographic analysis of busulfan for therapeutic drug monitoring

  2004cited by this paper
• Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.

  1996cited by this paper
• Use of a water-soluble busulfan formulation--pharmacokinetic studies in a canine model.

  1995cited by this paper
• Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics.

  1995cited by this paper
• Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?

  1994cited by this paper
• Busulfan bioavailability.

  1994cited by this paper
• Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.

  1993cited by this paper
• Busulfan disposition below the age of three: alteration in children with lysosomal storage disease.

  1993cited by this paper
• Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation.

  1992cited by this paper
• Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?

  1992cited by this paper
• Busulfan and veno-occlusive disease of the liver.

  1990cited by this paper
• Busulfan disposition in children.

  1990cited by this paper
• Busulfan and cyclophosphamide as conditioning regimen for autologous BMT in acute lymphoblastic leukemia.

  1989cited by this paper
• Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome.

  1988cited by this paper
• VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION

  1987cited by this paper
• Hepatic veno-occlusive disease.

  1986cited by this paper
• Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children.

  1986cited by this paper
• Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children.

  1986cited by this paper
• PRETRANSPLANT CONDITIONING WITH BUSULFAN (MYLERAN) AND CYCLOPHOSPHAMIDE FOR NONMALIGNANT DISEASES: ASSESSMENT OF ENGRAFTMENT FOLLOWING HISTOCOMPATIBLE ALLOGENEIC BONE MARROW TRANSPLANTATION

  1985cited by this paper
• THE CLINICAL COURSE OF 53 PATIENTS WITH VENOCCLUSIVE DISEASE OF THE LIVER AFTER MARROW TRANSPLANTATION

  1985cited by this paper
• Marrow transplantation for thalassaemia following busulphan and cyclophosphamide.

  1985cited by this paper
• Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors

  1984cited by this paper
• Determination of busulfan in plasma by GC-MS with selected-ion monitoring.

  1983cited by this paper
• A program package for simulation and parameter estimation in pharmacokinetic systems.

  1979cited by this paper
• Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults.

  1978cited by this paper

• Significance of busulfan administration route including therapeutic drug monitoring in the conditioning regimen of pediatric patients prior to hematopoietic stem cell transplantation

  2025cites this paper
• Limited Sampling Strategy Using End of Infusion and Six-Hour Concentrations Overestimates Intravenous Busulfan Clearance Compared With Standard Six-Point Sampling in Hematopoietic Stem Cell Transplant Patients

  2023cites this paper
• New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning

  2020cites this paper
• Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation

  2019cites this paper
• Evaluation of Limited Sampling Methods for Oral Busulfan Pharmacokinetic Monitoring in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation

  2016cites this paper
• Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.

  2015cites this paper
• Genetic and metabolic studies towards personalized conditioning regimen prior to stem cell transplantation

  2014cites this paper
• The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.

  2014cites this paper
• Comparison of Algorithms for Oral Busulphan Area Under the Concentration–Time Curve Limited Sampling Estimate

  2013cites this paper
• Limited Sampling Strategies to Estimate the Area under the Concentration-time Curve

  2012cites this paper
• PHARMACOLOGICAL STUDIES OF BUSULPHAN, CYCLOPHOSPHAMIDE AND TREOSULFAN IN THE CONDITIONING REGIMEN PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION

  2011cites this paper
• Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant

  2009cites this paper
• Quantitative Analysis of Busulfan in Human Plasma by LC-MS–MS

  2009cites this paper
• Population Pharmacokinetics of Oral Busulfan in Young Japanese Children Before Hematopoietic Stem Cell Transplantation

  2008cites this paper
• Beyond single nucleotide polimorphism

  2008cites this paper
• Mitochondria as a target for novel chemotherapeutic agents based on phenolic acids

  2008cites this paper
• Therapeutic drug monitoring of busulfan in transplantation.

  2008cites this paper
• A Systematic Review of Limited Sampling Strategies for Platinum Agents Used in Cancer Chemotherapy

  2007cites this paper
• Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring.

  2007cites this paper
• Simultaneous Determination of Busulphan in Plasma Samples by Liquid Chromatography‐electrospray Ionization Mass Spectrometry Utilizing Microextraction in Packed Syringe (MEPS) as On‐line Sample Preparation Method

  2007cites this paper
• Influence of Underlying Disease on Busulfan Disposition in Pediatric Bone Marrow Transplant Recipients: A Nonparametric Population Pharmacokinetic Study

  2007cites this paper
• Bone Marrow Transplantation for Acute Myeloid Leukemia in Children

  2006cites this paper
• Quantification of Busulfan in Saliva and Plasma in Haematopoietic Stem Cell Transplantation in Children

  2006cites this paper
• Development of a Pharmacokinetic and Bayesian Optimal Sampling Model for Individualization of Oral Busulfan in Hematopoietic Stem Cell Transplantation

  2006cites this paper
• Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation

  2005cites this paper
• Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.

  2005cites this paper
• Tandem Mass Spectrometry Method for the Quantification of Serum Busulfan

  2005cites this paper
• Pharmacokinetic variability of anticancer agents

  2005cites this paper
• Pharmacokinetics and limited sampling strategies of mycophenolic acid in lung transplant recipients

  2005cites this paper
• I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients

  2004cites this paper
• Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.

  2004cites this paper
• B harmacokinetics and Individualized Dose djustment of Intravenous Busulfan in Children with dvanced Hematologic Malignancies Undergoing llogeneic Stem Cell Transplantation

  2004cites this paper
• Pharmacokinetically guided dosing of (high-dose) chemotherapeutic agents

  2004cites this paper
• Retrospective appraisal of busulfan dose adjustment in children

  2003cites this paper
• On-Line Derivatization Utilizing Solid-Phase Microextraction (SPME) for Determination of Busulphan in Plasma Using Gas Chromatography–Mass Spectrometry (GC-MS)

  2003cites this paper
• The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation

  2003cites this paper
• Myeloablative conditioning regimens for AML allografts: 30 years later

  2003cites this paper
• The importance of pharmacokinetic limited sampling models for childhood cancer drug development.

  2003cites this paper
• The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo

  2002cites this paper
• Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques

  2002cites this paper
• Allogeneic Bone Marrow Transplantation in Children With Chronic Myelogenous Leukemia

  2002cites this paper
• A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m2 as a optimal total dose for conditioning

  2002cites this paper
• Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation

  2001cites this paper
• Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry. Application to pharmacokinetic studies in children.

  2001cites this paper
• Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation

  2001cites this paper
• Pharmacokinetics of liposomal busulphan in man

  2001cites this paper
• STUDIES ON MECHANISMS OF BUSULPHAN CYTOTOXICITY AND PHARMACOKINETICS

  2001cites this paper
• Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

  2001cites this paper
• Stability of busulfan in frozen plasma and whole blood samples.

  2001cites this paper
• Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens

  2001cites this paper
• We Stability of Busulfan in Frozen Plasma and Whole

  2001cites this paper
• Retrospective appraisal of busulfan dose adjustment in children

  2000cites this paper
• Plasma concentration monitoring of busulfan: does it improve clinical outcome?

  2000cites this paper
• Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies

  2000cites this paper
• Plasma Concentration Monitoring of Busulfan

  2000cites this paper
• Plasma Concentration Monitoring of BusulfanIt Improve Clinical Outcome

  2000cites this paper
• Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia

  2000cites this paper
• The clinical pharmacology of alkylating agents in high-dose chemotherapy.

  2000cites this paper
• The role of busulfan in bone marrow transplantation

  1999cites this paper
• Liposomal busulphan: bioavailability and effect on bone marrow in mice

  1998cites this paper
• Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration

  1998cites this paper